{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:17:05Z","timestamp":1782947825910,"version":"3.54.5"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"HealX Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurodevelop Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Fragile X syndrome (FXS) lacks FDA-approved treatments despite various small molecules contributing to phenotypic rescue in the\n                      <jats:italic>FMR1<\/jats:italic>\n                      knockout (KO) mouse model. Translation from the mouse model has been hampered by phenotypic heterogeneity that contributes to participation barriers among participants who are most affected and may be unable to regularly visit the research laboratory. The current study utilized a crossover design to test the acute neural and behavioral effects of a single 10\u00a0mg dose of gaboxadol and the reliability of electroencephalography (EEG) and behavioral data collected in participant homes compared to the clinic.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Ten adult males with full mutation FXS completed four blinded dosing visits (two placebo, two gaboxadol), with two occurring in-home and two in-lab. Pre- and post-dose assessments included resting high-density EEG, an auditory chirp paradigm, RBANS List Learning, and NIH Toolbox Cognition Battery subtests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No serious adverse events were reported. Compared with placebo, gaboxadol increased theta and alpha band power, with no interaction between collection environment (home vs. lab). Additionally, gaboxadol increased the proportion of electrodes with detectable low-frequency peaks and slowed the peak frequency. There were no effects on auditory-evoked measures or NIH Toolbox, with only a marginal effect on RBANS List Learning. An analysis of pre-dose EEG found reliability estimates across testing locations for all tested resting power and behavioral measures that were similar to in-lab reliability estimates found in the literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Single-dose gaboxadol augmented theta and alpha power in FXS during resting EEG, similar to previous findings in the typically developing population and in the\n                      <jats:italic>FMR1<\/jats:italic>\n                      KO, without normalizing gamma abnormalities, altering auditory-evoked responses, or contributing to behavioral change. These results did not significantly differ between the home and lab settings, supporting the feasibility of in-home data collection for clinical trials in FXS, including those that use complex measures such as EEG as endpoints.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>clinicaltrials.gov, NCT06334419, Registration Date: March 8, 2024.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s11689-026-09700-5","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:55:21Z","timestamp":1778223321000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gaboxadol increases resting theta and alpha power without affecting evoked responses in fragile X syndrome in a home-based setting"],"prefix":"10.1186","volume":"18","author":[{"given":"Lisa A.","family":"De Stefano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeonseok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli C.","family":"Dominick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest V.","family":"Pedapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Huckle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walker S.","family":"McKinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra L.","family":"Reisinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith N.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley E.","family":"Dapore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Miyakoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"issue":"1","key":"9700_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2018.308","volume":"6","author":"A Babayan","year":"2019","unstructured":"Babayan A, Erbey M, Kumral D, Reinelt JD, Reiter AMF, R\u00f6bbig J, et al. A mind-brain-body dataset of MRI, EEG, cognition, emotion, and peripheral physiology in young and old adults. Scientific Data. 2019;6(1):180308. https:\/\/doi.org\/10.1038\/sdata.2018.308.","journal-title":"Scientific Data"},{"issue":"9","key":"9700_CR2","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s10803-008-0564-8","volume":"38","author":"E Berry-Kravis","year":"2008","unstructured":"Berry-Kravis E, Sumis A, Kim O-K, Lara R, Wuu J. Characterization of potential outcome measures for future clinical trials in Fragile X Syndrome. J Autism Dev Disord. 2008;38(9):1751\u20137. https:\/\/doi.org\/10.1007\/s10803-008-0564-8.","journal-title":"J Autism Dev Disord"},{"key":"9700_CR3","doi-asserted-by":"publisher","unstructured":"Bigdely-Shamlo N, Mullen T, Kothe C, Su KM, Robbins KA. The PREP pipeline: Standardized preprocessing for large-scale EEG analysis. Frontiers in Neuroinformatics. 2015;9. https:\/\/doi.org\/10.3389\/fninf.2015.00016.","DOI":"10.3389\/fninf.2015.00016"},{"issue":"1","key":"9700_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-09633-8","volume":"12","author":"AE Boggs","year":"2022","unstructured":"Boggs AE, Schmitt LM, McLane RD, Adayev T, LaFauci G, Horn PS, et al. Optimization, validation and initial clinical implications of a Luminex-based immunoassay for the quantification of Fragile X Protein from dried blood spots. Sci Rep. 2022;12(1):5617. https:\/\/doi.org\/10.1038\/s41598-022-09633-8.","journal-title":"Sci Rep"},{"key":"9700_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.757825","volume":"12","author":"DB Budimirovic","year":"2021","unstructured":"Budimirovic DB, Dominick KC, Gabis LV, Adams M, Adera M, Huang L, et al. Gaboxadol in Fragile X Syndrome: a 12-week randomized, double-blind, parallel-group, Phase 2a study. Front Pharmacol. 2021;12:757825. https:\/\/doi.org\/10.3389\/fphar.2021.757825.","journal-title":"Front Pharmacol"},{"key":"9700_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2019.00141","volume":"13","author":"P Cogram","year":"2019","unstructured":"Cogram P, Deacon RMJ, Warner-Schmidt JL, Von Schimmelmann MJ, Abrahams BS, During MJ. Gaboxadol normalizes behavioral abnormalities in a mouse model of Fragile X Syndrome. Front Behav Neurosci. 2019;13:141. https:\/\/doi.org\/10.3389\/fnbeh.2019.00141.","journal-title":"Front Behav Neurosci"},{"issue":"1","key":"9700_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jneumeth.2003.10.009","volume":"134","author":"A Delorme","year":"2004","unstructured":"Delorme A, Makeig S. EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysis. J Neurosci Methods. 2004;134(1):9\u201321. https:\/\/doi.org\/10.1016\/j.jneumeth.2003.10.009.","journal-title":"J Neurosci Methods"},{"issue":"11","key":"9700_CR8","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1177\/0269881109105788","volume":"24","author":"D Dijk","year":"2010","unstructured":"Dijk D, James L, Peters S, Walsh J, Deacon S. Sex differences and the effect of gaboxadol and zolpidem on EEG power spectra in NREM and REM sleep. J Psychopharmacol. 2010;24(11):1613\u20138. https:\/\/doi.org\/10.1177\/0269881109105788.","journal-title":"J Psychopharmacol"},{"issue":"12","key":"9700_CR9","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41593-020-00744-x","volume":"23","author":"T Donoghue","year":"2020","unstructured":"Donoghue T, Haller M, Peterson EJ, Varma P, Sebastian P, Gao R, et al. Parameterizing neural power spectra into periodic and aperiodic components. Nat Neurosci. 2020;23(12):1655\u201365. https:\/\/doi.org\/10.1038\/s41593-020-00744-x.","journal-title":"Nat Neurosci"},{"key":"9700_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fnint.2019.00060","volume":"13","author":"LE Ethridge","year":"2019","unstructured":"Ethridge LE, De Stefano LA, Schmitt LM, Woodruff NE, Brown KL, Tran M, et al. Auditory EEG biomarkers in Fragile X Syndrome: clinical relevance. Front Integr Neurosci. 2019;13:60. https:\/\/doi.org\/10.3389\/fnint.2019.00060.","journal-title":"Front Integr Neurosci"},{"issue":"1","key":"9700_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13229-017-0140-1","volume":"8","author":"LE Ethridge","year":"2017","unstructured":"Ethridge LE, White SP, Mosconi MW, Wang J, Pedapati EV, Erickson CA, et al. Neural synchronization deficits linked to cortical hyper-excitability and auditory hypersensitivity in Fragile X Syndrome. Mol Autism. 2017;8(1):22. https:\/\/doi.org\/10.1186\/s13229-017-0140-1.","journal-title":"Mol Autism"},{"key":"9700_CR12","unstructured":"Gamer M, Lemon J, IFPS. Irr: Various Coefficients of Interrater Reliability and Agreement. R package version 0.84.1 . [Computer software]. 2019. https:\/\/CRAN.R-project.org\/package=irr."},{"key":"9700_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neuroimage.2017.06.078","volume":"158","author":"R Gao","year":"2017","unstructured":"Gao R, Peterson EJ, Voytek B. Inferring synaptic excitation\/inhibition balance from field potentials. Neuroimage. 2017;158:70\u20138. https:\/\/doi.org\/10.1016\/j.neuroimage.2017.06.078.","journal-title":"Neuroimage"},{"key":"9700_CR14","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.nbd.2019.01.002","volume":"124","author":"S Goswami","year":"2019","unstructured":"Goswami S, Cavalier S, Sridhar V, Huber KM, Gibson JR. Local cortical circuit correlates of altered EEG in the mouse model of Fragile X syndrome. Neurobiol Dis. 2019;124:563\u201372. https:\/\/doi.org\/10.1016\/j.nbd.2019.01.002.","journal-title":"Neurobiol Dis"},{"key":"9700_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2024.110182","volume":"262","author":"P Janz","year":"2025","unstructured":"Janz P, Bainier M, Marashli S, Gross S, Redondo RL. Clinically-probed mechanisms of action in Fragile-X syndrome fail to normalize translational EEG phenotypes in Fmr1 knockout mice. Neuropharmacology. 2025;262:110182. https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110182.","journal-title":"Neuropharmacology"},{"key":"9700_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104794","volume":"138","author":"CR Jonak","year":"2020","unstructured":"Jonak CR, Lovelace JW, Ethell IM, Razak KA, Binder DK. Multielectrode array analysis of EEG biomarkers in a mouse model of Fragile X Syndrome. Neurobiol Dis. 2020;138:104794. https:\/\/doi.org\/10.1016\/j.nbd.2020.104794.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"9700_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s11689-022-09455-9","volume":"14","author":"CR Jonak","year":"2022","unstructured":"Jonak CR, Pedapati EV, Schmitt LM, Assad SA, Sandhu MS, DeStefano L, et al. Baclofen-associated neurophysiologic target engagement across species in Fragile X Syndrome. J Neurodev Disord. 2022;14(1):52. https:\/\/doi.org\/10.1186\/s11689-022-09455-9.","journal-title":"J Neurodev Disord"},{"key":"9700_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-1749-8","author":"EG Jones","year":"1985","unstructured":"Jones EG. The Thalamus. Plenum Press. 1985. https:\/\/doi.org\/10.1007\/978-1-4615-1749-8.","journal-title":"Plenum Press"},{"key":"9700_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneumeth.2025.110465","volume":"420","author":"H Kim","year":"2025","unstructured":"Kim H, Chang C-Y, Kothe C, Iversen JR, Miyakoshi M. Juggler\u2019s ASR: unpacking the principles of artifact subspace reconstruction for revision toward extreme MoBI. J Neurosci Methods. 2025;420:110465. https:\/\/doi.org\/10.1016\/j.jneumeth.2025.110465.","journal-title":"J Neurosci Methods"},{"key":"9700_CR20","doi-asserted-by":"crossref","unstructured":"Kim H, Ethridge LE, De Stefano LA, Schmitt LM, Pedapati EV, Erickson CA, Miyakoshi M. Event-Related Spatio-Spectral Perturbation (ERSSP): A scalp-wide EEG analysis framework for capturing extralemniscal thalamocortical activity, validated using a fragile X Syndrome Model. 2025.","DOI":"10.1101\/2025.05.23.655841"},{"key":"9700_CR21","doi-asserted-by":"publisher","unstructured":"Kim H, Luo J, Chu S, Cannard C, Hoffmann S, Miyakoshi M. ICA\u2019s bug: How ghost ICs emerge from effective rank deficiency caused by EEG electrode interpolation and incorrect re-referencing. Front Signal Process. 2023; 3.https:\/\/doi.org\/10.3389\/frsip.2023.1064138.","DOI":"10.3389\/frsip.2023.1064138"},{"issue":"5","key":"9700_CR22","doi-asserted-by":"publisher","DOI":"10.1088\/1741-2560\/10\/5\/056014","volume":"10","author":"CA Kothe","year":"2013","unstructured":"Kothe CA, Makeig S. BCILAB: a platform for brain\u2013computer interface development. J Neural Eng. 2013;10(5):056014. https:\/\/doi.org\/10.1088\/1741-2560\/10\/5\/056014.","journal-title":"J Neural Eng"},{"issue":"5","key":"9700_CR23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nn.2303","volume":"12","author":"N Kriegeskorte","year":"2009","unstructured":"Kriegeskorte N, Simmons WK, Bellgowan PSF, Baker CI. Circular analysis in systems neuroscience: the dangers of double dipping. Nat Neurosci. 2009;12(5):535\u201340. https:\/\/doi.org\/10.1038\/nn.2303.","journal-title":"Nat Neurosci"},{"key":"9700_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bionps.2023.100070","volume":"9","author":"R Liu","year":"2023","unstructured":"Liu R, Pedapati EV, Schmitt LM, Shaffer RC, Smith EG, Dominick KC, et al. Reliability of resting-state electrophysiology in Fragile X Syndrome. Biomark Neuropsychiatry. 2023;9:100070. https:\/\/doi.org\/10.1016\/j.bionps.2023.100070.","journal-title":"Biomark Neuropsychiatry"},{"issue":"1","key":"9700_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/mrdd.20006","volume":"10","author":"DZ Loesch","year":"2004","unstructured":"Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in Fragile X. Ment Retard Dev Disabil Res Rev. 2004;10(1):31\u201341. https:\/\/doi.org\/10.1002\/mrdd.20006.","journal-title":"Ment Retard Dev Disabil Res Rev"},{"key":"9700_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.nbd.2018.03.012","volume":"115","author":"JW Lovelace","year":"2018","unstructured":"Lovelace JW, Ethell IM, Binder DK, Razak KA. Translation-relevant EEG phenotypes in a mouse model of Fragile X Syndrome. Neurobiol Dis. 2018;115:39\u201348. https:\/\/doi.org\/10.1016\/j.nbd.2018.03.012.","journal-title":"Neurobiol Dis"},{"issue":"8","key":"9700_CR27","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1177\/0269881111424457","volume":"26","author":"J Lundahl","year":"2012","unstructured":"Lundahl J, Deacon S, Maurice D, Staner L. EEG spectral power density profiles during NREM sleep for Gaboxadol and Zolpidem in patients with primary insomnia. J Psychopharmacol. 2012;26(8):1081\u20137. https:\/\/doi.org\/10.1177\/0269881111424457.","journal-title":"J Psychopharmacol"},{"key":"9700_CR28","doi-asserted-by":"publisher","DOI":"10.5664\/JCSM.1316","author":"J Ma","year":"2011","unstructured":"Ma J, Dijk D-J, Svetnik V, Tymofyeyev Y, Ray S, Walsh JK, et al. EEG power spectra response to a 4-h phase advance and Gaboxadol treatment in 822 men and women. Journal of Clinical Sleep Medicine. 2011. https:\/\/doi.org\/10.5664\/JCSM.1316.","journal-title":"Journal of Clinical Sleep Medicine"},{"issue":"4","key":"9700_CR29","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/sj.npp.1300641","volume":"30","author":"S Mathias","year":"2005","unstructured":"Mathias S, Zihl J, Steiger A, Lancel M. Effect of repeated Gaboxadol administration on night sleep and next-day performance in healthy elderly subjects. Neuropsychopharmacology. 2005;30(4):833\u201341. https:\/\/doi.org\/10.1038\/sj.npp.1300641.","journal-title":"Neuropsychopharmacology"},{"key":"9700_CR30","doi-asserted-by":"publisher","unstructured":"McKinney WS, Schmitt LM, De Stefano LA, Ethridge L, Norris JE, Horn PS, Dauterman S, Rosselot H, Pedapati EV, Reisinger DL, Dominick KC, Shaffer RC, Chin D, Friedman NR, Hong M, Sweeney JA, Erickson C. Results from a double-blind, randomized, placebo-controlled, single-dose, crossover trial of lovastatin or minocycline in fragile X Syndrome. J Child and Adolescent Psychopharmacol. 2024;0103. https:\/\/doi.org\/10.1089\/cap.2024.0103.","DOI":"10.1089\/cap.2024.0103"},{"key":"9700_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jneumeth.2016.04.015","volume":"268","author":"T Melman","year":"2016","unstructured":"Melman T, Victor JD. Robust power spectral estimation for EEG data. J Neurosci Methods. 2016;268:14\u201322. https:\/\/doi.org\/10.1016\/j.jneumeth.2016.04.015.","journal-title":"J Neurosci Methods"},{"issue":"5\u20136","key":"9700_CR32","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00429-010-0262-0","volume":"214","author":"V Menon","year":"2010","unstructured":"Menon V, Uddin LQ. Saliency, switching, attention and control: a network model of insula function. Brain Struct Funct. 2010;214(5\u20136):655\u201367. https:\/\/doi.org\/10.1007\/s00429-010-0262-0.","journal-title":"Brain Struct Funct"},{"key":"9700_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsad241","author":"M Miyakoshi","year":"2023","unstructured":"Miyakoshi M. Artifact subspace reconstruction: a candidate for a dream solution for EEG studies, sleep or awake. SLEEP. 2023. https:\/\/doi.org\/10.1093\/sleep\/zsad241.","journal-title":"SLEEP"},{"key":"9700_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/cercor\/bhaf141","author":"M Miyakoshi","year":"2025","unstructured":"Miyakoshi M, Kim H, De Stefano LA, Schmitt LM, Norris JE, Ethridge LE, et al. Hyper-extralemniscal model of Fragile X Syndrome. Cerebral Cortex. 2025. https:\/\/doi.org\/10.1093\/cercor\/bhaf141.","journal-title":"Cerebral Cortex"},{"key":"9700_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fninf.2020.597079","author":"M Miyakoshi","year":"2021","unstructured":"Miyakoshi M, Schmitt LM, Erickson CA, Sweeney JA, Pedapati EV. Can we push the \u201cquasi-perfect artifact rejection\u201d even closer to perfection? Front Neuroinform. 2021. https:\/\/doi.org\/10.3389\/fninf.2020.597079.","journal-title":"Front Neuroinform"},{"issue":"3","key":"9700_CR36","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.neuroimage.2010.09.084","volume":"54","author":"A Mouraux","year":"2011","unstructured":"Mouraux A, Diukova A, Lee MC, Wise RG, Iannetti GD. A multisensory investigation of the functional significance of the \u201cpain matrix.\u201d Neuroimage. 2011;54(3):2237\u201349. https:\/\/doi.org\/10.1016\/j.neuroimage.2010.09.084.","journal-title":"Neuroimage"},{"issue":"6","key":"9700_CR37","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1152\/jn.91181.2008","volume":"101","author":"A Mouraux","year":"2009","unstructured":"Mouraux A, Iannetti GD. Nociceptive laser-evoked brain potentials do not reflect nociceptive-specific neural activity. J Neurophysiol. 2009;101(6):3258\u201369. https:\/\/doi.org\/10.1152\/jn.91181.2008.","journal-title":"J Neurophysiol"},{"key":"9700_CR38","unstructured":"Mullen T. CleanLine. 2012. https:\/\/nitrc.org\/projects\/cleanline."},{"issue":"11","key":"9700_CR39","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1109\/tbme.2015.2481482","volume":"62","author":"TR Mullen","year":"2015","unstructured":"Mullen TR, Kothe CAE, Chi YM, Ojeda A, Kerth T, Makeig S, et al. Real-time neuroimaging and cognitive monitoring using wearable dry EEG. IEEE Trans Biomed Eng. 2015;62(11):2553\u201367. https:\/\/doi.org\/10.1109\/tbme.2015.2481482.","journal-title":"IEEE Trans Biomed Eng"},{"key":"9700_CR40","doi-asserted-by":"publisher","unstructured":"Norris JE, De Stefano LA, McKinney WS, Schmitt LM, Miyakoshi M, Gross C, Piloto S, Heald B, Pedapati EV, Erickson CA, Sweeney JA, Ethridge LE. Auditory steady-state response deficits in Fragile X Syndrome implicate deficits in stimulus representation maintenance and GABAergic modulation. Neurology. 2025. https:\/\/doi.org\/10.1101\/2025.01.29.25321365.","DOI":"10.1101\/2025.01.29.25321365"},{"issue":"5","key":"9700_CR41","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1159\/000332884","volume":"33","author":"JL Olmos-Serrano","year":"2011","unstructured":"Olmos-Serrano JL, Corbin JG, Burns MP. The GABAA receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of Fragile X Syndrome. Dev Neurosci. 2011;33(5):395\u2013403. https:\/\/doi.org\/10.1159\/000332884.","journal-title":"Dev Neurosci"},{"issue":"29","key":"9700_CR42","doi-asserted-by":"publisher","first-page":"9929","DOI":"10.1523\/JNEUROSCI.1714-10.2010","volume":"30","author":"JL Olmos-Serrano","year":"2010","unstructured":"Olmos-Serrano JL, Paluszkiewicz SM, Martin BS, Kaufmann WE, Corbin JG, Huntsman MM. Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of Fragile X Syndrome. J Neurosci. 2010;30(29):9929\u201338. https:\/\/doi.org\/10.1523\/JNEUROSCI.1714-10.2010.","journal-title":"J Neurosci"},{"key":"9700_CR43","unstructured":"Ovid Therapeutics, Inc. (2022). Investigator\u2019s Brochure. Ovid Therapeutics, Inc."},{"issue":"1","key":"9700_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-022-03395-9","volume":"5","author":"EV Pedapati","year":"2022","unstructured":"Pedapati EV, Schmitt LM, Ethridge LE, Miyakoshi M, Sweeney JA, Liu R, et al. Neocortical localization and thalamocortical modulation of neuronal hyperexcitability contribute to Fragile X Syndrome. Commun Biol. 2022;5(1):442. https:\/\/doi.org\/10.1038\/s42003-022-03395-9.","journal-title":"Commun Biol"},{"issue":"4","key":"9700_CR45","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/s0306-4522(00)00442-5","volume":"101","author":"S Pirker","year":"2000","unstructured":"Pirker S, Schwarzer C, Wieselthaler A, Sieghart W, Sperk G. GABAA receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience. 2000;101(4):815\u201350. https:\/\/doi.org\/10.1016\/s0306-4522(00)00442-5.","journal-title":"Neuroscience"},{"key":"9700_CR46","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing [Computer software]. R Foundation for Statistical Computing; 2024. https:\/\/www.R-project.org."},{"issue":"3","key":"9700_CR47","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1076\/jcen.20.3.310.823","volume":"20","author":"C Randolph","year":"1998","unstructured":"Randolph C, Tierney MC, Mohr E, Chase TN. The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20(3):310\u20139. https:\/\/doi.org\/10.1076\/jcen.20.3.310.823.","journal-title":"J Clin Exp Neuropsychol"},{"key":"9700_CR48","doi-asserted-by":"publisher","unstructured":"Redondo R, Duarte JM, Janz P, Bruns A, Gross S, Bainier M, Debilly S, Sch\u00f6ppenthau S, Bielser T, Kuennecke B, Schulz J. Hyperactivation of distinct thalamic nuclei differentially impairs sleep physiology in rats. Springer Science and Business Media LLC; 2025. https:\/\/doi.org\/10.21203\/rs.3.rs-6809066\/v1","DOI":"10.21203\/rs.3.rs-6809066\/v1"},{"key":"9700_CR49","volume-title":"The stanford-binet intelligence scales","author":"GH Roid","year":"2012","unstructured":"Roid GH, Pomplun M. The stanford-binet intelligence scales, vol. Vol. 654. New York, NY, USA: The Guilford Press; 2012."},{"issue":"1 vol.","key":"9700_CR50","first-page":"210","volume":"27","author":"J Rose","year":"1948","unstructured":"Rose J, Woolsey C. The orbitofrontal cortex and its connections with the mediodorsal nucleus in rabbit, sheep and cat. Res Publ Assoc Res Nerv Ment Dis. 1948;27(1 vol.):210\u201332.","journal-title":"Res Publ Assoc Res Nerv Ment Dis"},{"issue":"1","key":"9700_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/1866-1955-6-16","volume":"6","author":"SM Sansone","year":"2014","unstructured":"Sansone SM, Schneider A, Bickel E, Berry-Kravis E, Prescott C, Hessl D. Improving IQ measurement in intellectual disabilities using true deviation from population norms. J Neurodev Disord. 2014;6(1):16. https:\/\/doi.org\/10.1186\/1866-1955-6-16.","journal-title":"J Neurodev Disord"},{"issue":"5","key":"9700_CR52","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.tins.2004.03.005","volume":"27","author":"A Semyanov","year":"2004","unstructured":"Semyanov A, Walker MC, Kullmann DM, Silver RA. Tonically active GABAA receptors: modulating gain and maintaining the tone. Trends Neurosci. 2004;27(5):262\u20139. https:\/\/doi.org\/10.1016\/j.tins.2004.03.005.","journal-title":"Trends Neurosci"},{"issue":"12","key":"9700_CR53","doi-asserted-by":"publisher","first-page":"e1229","DOI":"10.1212\/WNL.0000000000009131","volume":"94","author":"RH Shields","year":"2020","unstructured":"Shields RH, Kaat AJ, McKenzie FJ, Drayton A, Sansone SM, Coleman J, et al. Validation of the NIH Toolbox Cognitive Battery in intellectual disability. Neurology. 2020;94(12):e1229-40. https:\/\/doi.org\/10.1212\/WNL.0000000000009131.","journal-title":"Neurology"},{"issue":"10","key":"9700_CR54","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1093\/cercor\/bhab352","volume":"32","author":"R Somervail","year":"2022","unstructured":"Somervail R, Bufacchi RJ, Salvatori C, Neary-Zajiczek L, Guo Y, Novembre G, et al. Brain responses to surprising stimulus offsets: phenomenology and functional significance. Cereb Cortex. 2022;32(10):2231\u201344. https:\/\/doi.org\/10.1093\/cercor\/bhab352.","journal-title":"Cereb Cortex"},{"key":"9700_CR55","doi-asserted-by":"publisher","unstructured":"SomervailR, Perovic S, Bufacchi RJ, Caminiti R, Iannetti D. A two-system theory of sensory-evoked brain responses. Brain. 2025. https:\/\/doi.org\/10.1093\/brain\/awaf402.","DOI":"10.1093\/brain\/awaf402"},{"issue":"2","key":"9700_CR56","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/cercor\/bhaa267","volume":"31","author":"R Somervail","year":"2021","unstructured":"Somervail R, Zhang F, Novembre G, Bufacchi RJ, Guo Y, Crepaldi M, et al. Waves of change: brain sensitivity to differential, not absolute, stimulus intensity is conserved across humans and rats. Cereb Cortex. 2021;31(2):949\u201360. https:\/\/doi.org\/10.1093\/cercor\/bhaa267.","journal-title":"Cereb Cortex"},{"issue":"3","key":"9700_CR57","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1124\/jpet.105.092403","volume":"316","author":"S\u00cd St\u00f3rustovu","year":"2006","unstructured":"St\u00f3rustovu S\u00cd, Ebert B. Pharmacological characterization of agonists at \u03b4-containing GABAA receptors: functional selectivity for extrasynaptic receptors is dependent on the absence of \u03b32. J Pharmacol Exp Ther. 2006;316(3):1351\u20139. https:\/\/doi.org\/10.1124\/jpet.105.092403.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"9700_CR58","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1152\/jn.1975.38.5.1284","volume":"38","author":"T Tanabe","year":"1975","unstructured":"Tanabe T, Iino M, Takagi SF. Discrimination of odors in olfactory bulb, pyriform-amygdaloid areas, and orbitofrontal cortex of the monkey. J Neurophysiol. 1975;38(5):1284\u201396.","journal-title":"J Neurophysiol"},{"issue":"5","key":"9700_CR59","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/sleep\/30.5.593","volume":"30","author":"JK Walsh","year":"2007","unstructured":"Walsh JK, Deacon S, Dijk D-J, Lundahl J. The selective extrasynaptic GABAA agonist, Gaboxadol, improves traditional hypnotic efficacy measures and enhances slow wave activity in a model of transient insomnia. Sleep. 2007;30(5):593\u2013602. https:\/\/doi.org\/10.1093\/sleep\/30.5.593.","journal-title":"Sleep"},{"issue":"1","key":"9700_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s11689-017-9191-z","volume":"9","author":"J Wang","year":"2017","unstructured":"Wang J, Ethridge LE, Mosconi MW, White SP, Binder DK, Pedapati EV, et al. A resting EEG study of neocortical hyperexcitability and altered functional connectivity in fragile X syndrome. J Neurodev Disord. 2017;9(1):11. https:\/\/doi.org\/10.1186\/s11689-017-9191-z.","journal-title":"J Neurodev Disord"},{"issue":"4","key":"9700_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/mono.12031","volume":"78","author":"S Weintraub","year":"2013","unstructured":"Weintraub S, Bauer PJ, Zelazo PD, Wallner\u2010Allen K, Dikmen SS, Heaton RK, et al. I. NIH toolbox cognition battery (CB): introduction and pediatric data. Monogr Soc Res Child Dev. 2013;78(4):1\u201315. https:\/\/doi.org\/10.1111\/mono.12031.","journal-title":"Monogr Soc Res Child Dev"},{"issue":"1","key":"9700_CR62","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1152\/jn.1980.43.1.69","volume":"43","author":"H Yarita","year":"1980","unstructured":"Yarita H, Iino M, Tanabe T, Kogure S, Takagi SF. A transthalamic olfactory pathway to orbitofrontal cortex in the monkey. J Neurophysiol. 1980;43(1):69\u201385. https:\/\/doi.org\/10.1152\/jn.1980.43.1.69.","journal-title":"J Neurophysiol"}],"container-title":["Journal of Neurodevelopmental Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11689-026-09700-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-026-09700-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-026-09700-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T22:34:41Z","timestamp":1782945281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s11689-026-09700-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9700"],"URL":"https:\/\/doi.org\/10.1186\/s11689-026-09700-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7871579\/v1","asserted-by":"object"}]},"ISSN":["1866-1955"],"issn-type":[{"value":"1866-1955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Cincinnati Children\u2019s Hospital Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This work was sponsored by HealX pharmaceuticals who both supplied the gaboxadol and matching placebo and paid for the work to be conducted at Cincinnati Children\u2019s Hospital Medical Center.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}